<div id="displayContant">
<br><div class="long-title">
<span>Sovaldi</span><span> (
					SOFOSBUVIR
				)</span>
</div>
<br><div class="section"><div id="SOVALDI_collapsableElement_48780-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"></div></div></div>
<div class="section"><div id="SOVALDI_collapsableElement_43683-2" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                        <table width="100%" stylecode="Noautorules">
                           <colgroup><col width="80%" align="left" valign="top">
                           <col width="20%" align="right" valign="top">
                           </colgroup><tbody>
                              <tr>
                                 <td>Indications and Usage (<a href="#S1">1</a>)</td>
                                 <td>08/2015</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration  (<a href="#S2.1">2.1</a>, <a href="#S2.2">2.2</a>)</td>
                                 <td>08/2015</td>
                              </tr>
                              <tr>
                                 <td>Contraindications (<a href="#S4">4</a>)</td>
                                 <td>08/2015</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<a href="#S5.1">5.1</a>)</td>
                                 <td>03/2015</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<a href="#S5.2">5.2</a>, <a href="#S5.3">5.3</a>, <a href="#S5.4">5.4</a>)</td>
                                 <td>08/2015</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div></div></div>
<div class="section">
<div id="nonCollapsableElement_34067-9">
<div class="drugSubheadings">
<span id="SOVALDI_34067-9" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>1 INDICATIONS AND USAGE</div>
<div id="SOVALDI_previewText_34067-9" class="previewText">
                  
                     SOVALDI is indicated for the treatment 
                        SOVALDI is a hepatitis C virus (HCV) nucleotide analog <span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34067-9" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <p>
                     <content stylecode="xmChange">SOVALDI is indicated for the treatment of genotype 1, 2, 3 or 4 chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen <content stylecode="italics"> [see <a href="#S14">Clinical Studies (14)</a>]</content>.</content>
                  </p>
               </text><text>
                        <p>SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of genotype 1, 2, 3 or 4 chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen. (<a href="#S1">1</a>)</p>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34068-7">
<div class="drugSubheadings">
<span id="SOVALDI_34068-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>2	DOSAGE AND ADMINISTRATION</div>
<div id="SOVALDI_previewText_34068-7" class="previewText">
                        
                           One 400 mg tablet taken onc<span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34068-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>One 400 mg tablet taken once daily with or without food. (<a href="#S2.1">2.1</a>)</li>
                           <li>Should be used in combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of HCV. Recommended combination therapy: (<a href="#S2.1">2.1</a>)</li>
                        </ul>
                        <table width="100%">
                           <colgroup><col width="39%" align="center" valign="middle">
                           <col width="38%" align="center" valign="middle">
                           <col width="23%" align="center" valign="middle">
                           </colgroup><thead>
                              <tr>
                                 <th stylecode="Lrule Rrule" valign="bottom">Patient Population</th>
                                 <th stylecode="Rrule" valign="bottom">Treatment</th>
                                 <th stylecode="Rrule" valign="bottom">Duration</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td stylecode="Lrule Rrule Botrule">Genotype 1 or 4</td>
                                 <td stylecode="Rrule Botrule">SOVALDI + peg-interferon alfa + ribavirin</td>
                                 <td stylecode="Rrule Botrule">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule Botrule">Genotype 2</td>
                                 <td stylecode="Rrule Botrule">SOVALDI + ribavirin</td>
                                 <td stylecode="Rrule Botrule">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">Genotype 3</td>
                                 <td stylecode="Rrule">SOVALDI + ribavirin</td>
                                 <td stylecode="Rrule">24 weeks</td>
                              </tr>
                           </tbody>
                        </table>
                        <ul ultype="unordered">
                           <li>HCV/HIV-1 co-infection: For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in the table above. (<a href="#S2.1">2.1</a>)</li>
                           <li>SOVALDI in combination with ribavirin for 24 weeks can be considered for patients with genotype 1 infection who are interferon ineligible. (<a href="#S2.1">2.1</a>)</li>
                           <li>Should be used in combination with ribavirin for treatment of HCV in patients with hepatocellular carcinoma awaiting liver transplantation for up to 48 weeks or until liver transplantation, whichever occurs first. (<a href="#S2.1">2.1</a>)</li>
                           <li>A dosage recommendation cannot be made for patients with severe renal impairment or end stage renal disease. (<a href="#S2.4">2.4</a>, <a href="#S8.6">8.6</a>)</li>
                        </ul>
                     </text></div>
<span id="SOVALDI_collapsableElement_2_1" class="safetySubheading">2.1	Recommended Dosage</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The recommended dosage of SOVALDI is one 400 mg tablet, taken orally, once daily with or without food <content stylecode="italics"> [see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>.</p>
                        <p>Administer SOVALDI in combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of HCV. The recommended treatment regimen and duration for SOVALDI combination therapy is provided in Table 1.</p>
                        <p>
                           <content stylecode="xmChange">For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. Refer to <content stylecode="italics"> Drug Interactions (7) </content> for dosage recommendations for concomitant HIV-1 antiviral drugs.</content>
                        </p>
                        <table width="75%" id="table1">
                           <caption>Table 1	Recommended Treatment Regimens and Duration</caption>
                           <colgroup><col width="40%" align="left" valign="middle">
                           <col width="38%" align="center" valign="middle">
                           <col width="22%" align="center" valign="middle">
                           </colgroup><thead>
                              <tr>
                                 <th stylecode="Lrule Rrule">
                                    <content stylecode="xmChange">Patient Population</content>
                                 </th>
                                 <th stylecode="Rrule">Treatment Regimen</th>
                                 <th stylecode="Rrule">Duration</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="xmChange">Genotype 1 or 4</content>
                                 </td>
                                 <td stylecode="Rrule">SOVALDI + peginterferon alfa<footnote id="t1f1">See peginterferon alfa prescribing information for dosage recommendation for patients with genotype 1 or 4 HCV.</footnote> + ribavirin<footnote id="t1f2">Dosage of ribavirin is weight-based (&lt;75 kg = 1000 mg and ≥75 kg = 1200 mg). The daily dosage of ribavirin is administered orally in two divided doses with food. Patients with renal impairment (CrCl ≤50 mL/min) require ribavirin dosage reduction; refer to ribavirin prescribing information.</footnote>
                                 </td>
                                 <td stylecode="Rrule">12 weeks</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="xmChange">Genotype 2</content>
                                 </td>
                                 <td stylecode="Rrule">SOVALDI + ribavirin<footnoteref idref="t1f2"></footnoteref>
                                 </td>
                                 <td stylecode="Rrule">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="xmChange">Genotype 3</content>
                                 </td>
                                 <td stylecode="Rrule">SOVALDI + ribavirin<footnoteref idref="t1f2"></footnoteref>
                                 </td>
                                 <td stylecode="Rrule">24 weeks</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Patients with Genotype 1 HCV Who are Ineligible to Receive an Interferon-Based Regimen</content>
                              </p>
                              <p>SOVALDI in combination with ribavirin for 24 weeks can be considered as a therapeutic option for patients with genotype 1 infection who are ineligible to receive an interferon-based regimen <content stylecode="italics"> [see <a href="#S14.4">Clinical Studies (14.4)</a>]</content>. Treatment decision should be guided by an assessment of the potential benefits and risks for the individual patient.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation</content>
                              </p>
                              <p>Administer SOVALDI in combination with ribavirin for up to 48 weeks or until the time of liver transplantation, whichever occurs first, to prevent post-transplant HCV reinfection <content stylecode="italics"> [see <a href="#S8.8">Use in Specific Populations (8.8)</a>]</content>.</p>
                           </text></div>
<span id="SOVALDI_collapsableElement_2_2" class="safetySubheading">2.2 Dosage Modification</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Dosage reduction of SOVALDI is not recommended.</p>
                        <p>
                           <content stylecode="xmChange">If a patient has a serious adverse reaction potentially related to peginterferon alfa and/or ribavirin, the peginterferon alfa and/or ribavirin dosage should be reduced or discontinued, if appropriate, until the adverse reaction abates or decreases in severity. Refer to the peginterferon alfa and ribavirin prescribing information for additional information about how to reduce and/or discontinue the peginterferon alfa and/or ribavirin dosage.</content>
                        </p>
                     </text></div>
<span id="SOVALDI_collapsableElement_2_3" class="safetySubheading">2.3 	Discontinuation of Dosing</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>If the other agents used in combination with SOVALDI are permanently discontinued, SOVALDI should also be discontinued.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_2_4" class="safetySubheading">2.4 	Severe Renal Impairment and End Stage Renal Disease</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>No dosage recommendation can be given for patients with severe renal impairment (estimated Glomerular Filtration Rate [eGFR] less than 30 mL/min/1.73m<sup>2</sup>) or with end stage renal disease (ESRD) due to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite <content stylecode="italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a> and <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</content>.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43678-2">
<div class="drugSubheadings">
<span id="SOVALDI_43678-2" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>3	DOSAGE FORMS AND STRENGTHS</div>
<div id="SOVALDI_previewText_43678-2" class="previewText">
                  SOVALDI is available as a yellow-colored, capsule-shaped, fil
                        Tablets: 400 mg. (3)
                     <span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_43678-2" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <p>SOVALDI is available as a yellow-colored, capsule-shaped, film-coated tablet debossed with "GSI" on one side and "7977" on the other side. Each tablet contains 400 mg sofosbuvir.</p>
               </text><text>
                        <p>Tablets: 400 mg. (<a href="#S3">3</a>)</p>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34070-3">
<div class="drugSubheadings">
<span id="SOVALDI_34070-3" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>4	CONTRAINDICATIONS</div>
<div id="SOVALDI_previewText_34070-3" class="previewText">
                  
                     When SOVALDI is used in combination wit
                        
                           When used in combination wi<span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34070-3" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <p>
                     <content stylecode="xmChange">When SOVALDI is used in combination with ribavirin or peginterferon alfa/ribavirin, the contraindications applicable to those agents are applicable to combination therapies. Refer to the prescribing information of peginterferon alfa and ribavirin for a ul of their contraindications.</content>
                  </p>
               </text><text>
                        <ul ultype="unordered">
                           <li>When used in combination with peginterferon alfa/ribavirin or ribavirin alone, all contraindications to peginterferon alfa and/or ribavirin also apply to SOVALDI combination therapy. (<a href="#S4">4</a>)</li>
                        </ul>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_43685-7">
<div class="drugSubheadings">
<span id="SOVALDI_43685-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>5	WARNINGS AND PRECAUTIONS</div>
<div id="SOVALDI_previewText_43685-7" class="previewText">
                        
                           Bradycardia with amiodarone<span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_43685-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>Bradycardia with amiodarone coadministration: Serious symptomatic bradycardia may occur in patients taking amiodarone and SOVALDI in combination with another direct acting antiviral (DAA), particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. Coadministration of amiodarone with SOVALDI in combination with another DAA is not recommended. In patients without alternative, viable treatment options, cardiac monitoring is recommended. (<a href="#S5.1">5.1</a>, <a href="#S6.2">6.2</a>,<a href="#S7.1">7.1</a>)</li>
                           <li>Use with other drugs containing sofosbuvir is not recommended (<a href="#S5.4">5.4</a>)</li>
                        </ul>
                     </text></div>
<span id="SOVALDI_collapsableElement_5_1" class="safetySubheading">5.1 	Serious Symptomatic Bradycardia When Coadministered with Amiodarone and Another HCV Direct Acting Antiviral</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="xmChange">Postmarketing cases of symptomatic bradycardia and cases requiring pacemaker intervention have been reported when amiodarone is coadministered with SOVALDI in combination with an investigational agent (NS5A inhibitor) or simeprevir. A fatal cardiac arrest was reported in a patient receiving a sofosbuvir-containing regimen (HARVONI (ledipasvir/sofosbuvir)). Bradycardia has generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating HCV treatment. Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. Bradycardia generally resolved after discontinuation of HCV treatment. The mechanism for this effect is unknown.</content>
                        </p>
                        <p>
                           <content stylecode="xmChange">Coadministration of amiodarone with SOVALDI in combination with another direct acting antiviral (DAA) is not recommended. For patients taking amiodarone who have no other alternative, viable treatment options and who will be coadministered SOVALDI and another DAA:</content>
                        </p>
                        <ul ultype="unordered">
                           <li>
                              <content stylecode="xmChange">Counsel patients about the risk of serious symptomatic bradycardia</content>
                           </li>
                           <li>
                              <content stylecode="xmChange">Cardiac monitoring in an in-patient setting for the first 48 hours of coadministration is recommended, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment.</content>
                           </li>
                        </ul>
                        <p>
                           <content stylecode="xmChange">Patients who are taking SOVALDI in combination with another DAA who need to start amiodarone therapy due to no other alternative, viable treatment options should undergo similar cardiac monitoring as outlined above.</content>
                        </p>
                        <p>
                           <content stylecode="xmChange">Due to amiodarone's long half-life, patients discontinuing amiodarone just prior to starting SOVALDI in combination with a DAA should also undergo similar cardiac monitoring as outlined above.</content>
                        </p>
                        <p>
                           <content stylecode="xmChange">Patients who develop signs or symptoms of bradycardia should seek medical evaluation immediately. Symptoms may include near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pains, confusion or memory problems <content stylecode="italics"> [see <a href="#S6.2">Adverse Reactions (6.2)</a>, <a href="#S7.1">Drug Interactions (7.1)</a>]</content>.</content>
                        </p>
                     </text></div>
<span id="SOVALDI_collapsableElement_5_2" class="safetySubheading">5.2 	Risk of Reduced Therapeutic Effect Due to Use with P-gp Inducers</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="xmChange">Drugs that are P-gp inducers in the intestine (e.g., rifampin, St. John's wort) may significantly decrease sofosbuvir plasma concentrations and may lead to a reduced therapeutic effect of SOVALDI.  The use of rifampin and St. John's wort with SOVALDI is not recommended <content stylecode="italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</content>.</content>
                        </p>
                     </text></div>
<span id="SOVALDI_collapsableElement_5_3" class="safetySubheading">5.3	Risks Associated with Combination Treatment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="xmChange">Because SOVALDI is used in combination with other antiviral drugs for treatment of HCV infection, consult the prescribing information for these drugs used in combination with SOVALDI. Warnings and Precautions related to these drugs also apply to their use in SOVALDI combination treatment.</content>
                        </p>
                     </text></div>
<span id="SOVALDI_collapsableElement_5_4" class="safetySubheading">5.4	Related Products Not Recommended</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="xmChange">The use of SOVALDI with other products containing sofosbuvir is not recommended.</content>
                        </p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34084-4">
<div class="drugSubheadings">
<span id="SOVALDI_34084-4" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>6	ADVERSE REACTIONS</div>
<div id="SOVALDI_previewText_34084-4" class="previewText">
                  The following serious adverse reactions are described below a
                        The most common adverse events (incidence greater than <span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34084-4" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText">
<text>
                  <p>The following serious adverse reactions are described below and elsewhere in the labeling:</p>
                  <ul ultype="unordered">
                     <li>Serious Symptomatic Bradycardia When Coadministered with Amiodarone and Another HCV Direct Acting Antiviral <content stylecode="italics"> [see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</content>.</li>
                  </ul>
               </text><text>
                        <p>The most common adverse events (incidence greater than or equal to 20%, all grades) observed with SOVALDI in combination with ribavirin were fatigue and headache. The most common adverse events observed with SOVALDI in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia and anemia. (<a href="#S6.1">6.1</a>)</p>
                        <br>
                        <p>
                           <content stylecode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </p>
                     </text>
</div>
<span id="SOVALDI_collapsableElement_6_1" class="safetySubheading">6.1	Clinical Trials Experience</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
                        <p>When SOVALDI is administered with ribavirin or peginterferon alfa/ribavirin, refer to the respective prescribing information for a description of adverse reactions associated with their use.</p>
                        <p>The safety assessment of SOVALDI was based on pooled Phase 3 clinical trial data (both controlled and uncontrolled) including:</p>
                        <ul ultype="unordered">
                           <li>650 subjects who received SOVALDI + ribavirin (RBV) combination therapy for 12 weeks,</li>
                           <li>98 subjects who received SOVALDI + ribavirin combination therapy for 16 weeks,</li>
                           <li>250 subjects who received SOVALDI + ribavirin combination therapy for 24 weeks,</li>
                           <li>327 subjects who received SOVALDI + peginterferon (Peg-IFN) alfa + ribavirin combination therapy for 12 weeks,</li>
                           <li>243 subjects who received peginterferon alfa + ribavirin for 24 weeks, and </li>
                           <li>71 subjects who received placebo (PBO) for 12 weeks <content stylecode="italics">[see <a href="#S14">Clinical Studies (14)</a>]</content>.</li>
                        </ul>
                        <p>The proportion of subjects who permanently discontinued treatment due to adverse events was 4% for subjects receiving placebo, 1% for subjects receiving SOVALDI + ribavirin for 12 weeks, less than 1% for subjects receiving SOVALDI + ribavirin for 24 weeks, 11% for subjects receiving peginterferon alfa + ribavirin for 24 weeks and 2% for subjects receiving SOVALDI + peginterferon alfa + ribavirin for 12 weeks.</p>
                        <p>Adverse events observed in at least 15% of subjects in the Phase 3 clinical trials outlined above are provided in Table 2. A side-by-side tabulation is displayed to simplify presentation; direct comparison across trials should not be made due to differing trial designs.</p>
                        <p>The most common adverse events (at least 20%) for SOVALDI + ribavirin combination therapy were fatigue and headache. The most common adverse events (at least 20%) for SOVALDI + peginterferon alfa + ribavirin combination therapy were fatigue, headache, nausea, insomnia and anemia.</p>
                        <table width="75%" id="table2">
                           <caption>Table 2	Adverse Events (All Grades and without Regard to Causality) Reported in ≥15% of Subjects with HCV in Any Treatment Arm</caption>
                           <colgroup><col width="17%" align="left" valign="top">
                           <col width="12%" align="center" valign="middle">
                           <col width="17%" align="center" valign="middle">
                           <col width="17%" align="center" valign="middle">
                           <col width="18%" align="center" valign="middle">
                           <col width="19%" align="center" valign="middle">
                           </colgroup><thead>
                              <tr stylecode="Botrule">
                                 <th stylecode="Lrule Rrule"></th>
                                 <th colspan="3" stylecode="Rrule">Interferon-free Regimens</th>
                                 <th colspan="2" stylecode="Rrule">Interferon-containing Regimens</th>
                              </tr>
                              <tr>
                                 <th stylecode="Lrule Rrule"></th>
                                 <th stylecode="Rrule Botrule">PBO<br> 12 weeks</th>
                                 <th stylecode="Rrule Botrule">SOVALDI + RBV<footnote id="t2f1">Subjects received weight-based ribavirin (1000 mg per day if weighing &lt;75 kg or 1200 mg per day if weighing ≥75 kg).</footnote>
                                    <br>12 weeks</th>
                                 <th stylecode="Rrule Botrule">SOVALDI + RBV<footnoteref idref="t2f1"></footnoteref>
                                    <br>24 weeks</th>
                                 <th stylecode="Rrule Botrule">Peg-IFN alfa + RBV<footnote id="K1384">Subjects received 800 mg ribavirin per day regardless of weight.</footnote>
                                    <br>24 weeks</th>
                                 <th stylecode="Rrule Botrule">SOVALDI + Peg-IFN alfa + RBV<footnoteref idref="t2f1"></footnoteref>
                                    <br>12 weeks</th>
                              </tr>
                              <tr>
                                 <th stylecode="Lrule Rrule"></th>
                                 <th stylecode="Rrule">N=71</th>
                                 <th stylecode="Rrule">N=650</th>
                                 <th stylecode="Rrule">N=250</th>
                                 <th stylecode="Rrule">N=243</th>
                                 <th stylecode="Rrule">N=327</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Fatigue</td>
                                 <td stylecode="Rrule">24%</td>
                                 <td stylecode="Rrule">38%</td>
                                 <td stylecode="Rrule">30%</td>
                                 <td stylecode="Rrule">55%</td>
                                 <td stylecode="Rrule">59%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Headache</td>
                                 <td stylecode="Rrule">20%</td>
                                 <td stylecode="Rrule">24%</td>
                                 <td stylecode="Rrule">30%</td>
                                 <td stylecode="Rrule">44%</td>
                                 <td stylecode="Rrule">36%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Nausea</td>
                                 <td stylecode="Rrule">18%</td>
                                 <td stylecode="Rrule">22%</td>
                                 <td stylecode="Rrule">13%</td>
                                 <td stylecode="Rrule">29%</td>
                                 <td stylecode="Rrule">34%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Insomnia</td>
                                 <td stylecode="Rrule">4%</td>
                                 <td stylecode="Rrule">15%</td>
                                 <td stylecode="Rrule">16%</td>
                                 <td stylecode="Rrule">29%</td>
                                 <td stylecode="Rrule">25%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Pruritus</td>
                                 <td stylecode="Rrule">8%</td>
                                 <td stylecode="Rrule">11%</td>
                                 <td stylecode="Rrule">27%</td>
                                 <td stylecode="Rrule">17%</td>
                                 <td stylecode="Rrule">17%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Anemia</td>
                                 <td stylecode="Rrule">0%</td>
                                 <td stylecode="Rrule">10%</td>
                                 <td stylecode="Rrule">6%</td>
                                 <td stylecode="Rrule">12%</td>
                                 <td stylecode="Rrule">21%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Asthenia</td>
                                 <td stylecode="Rrule">3%</td>
                                 <td stylecode="Rrule">6%</td>
                                 <td stylecode="Rrule">21%</td>
                                 <td stylecode="Rrule">3%</td>
                                 <td stylecode="Rrule">5%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Rash</td>
                                 <td stylecode="Rrule">8%</td>
                                 <td stylecode="Rrule">8%</td>
                                 <td stylecode="Rrule">9%</td>
                                 <td stylecode="Rrule">18%</td>
                                 <td stylecode="Rrule">18%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Decreased Appetite</td>
                                 <td stylecode="Rrule">10%</td>
                                 <td stylecode="Rrule">6%</td>
                                 <td stylecode="Rrule">6%</td>
                                 <td stylecode="Rrule">18%</td>
                                 <td stylecode="Rrule">18%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Chills</td>
                                 <td stylecode="Rrule">1%</td>
                                 <td stylecode="Rrule">2%</td>
                                 <td stylecode="Rrule">2%</td>
                                 <td stylecode="Rrule">18%</td>
                                 <td stylecode="Rrule">17%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Influenza Like Illness</td>
                                 <td stylecode="Rrule">3%</td>
                                 <td stylecode="Rrule">3%</td>
                                 <td stylecode="Rrule">6%</td>
                                 <td stylecode="Rrule">18%</td>
                                 <td stylecode="Rrule">16%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Pyrexia</td>
                                 <td stylecode="Rrule">0%</td>
                                 <td stylecode="Rrule">4%</td>
                                 <td stylecode="Rrule">4%</td>
                                 <td stylecode="Rrule">14%</td>
                                 <td stylecode="Rrule">18%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Diarrhea</td>
                                 <td stylecode="Rrule">6%</td>
                                 <td stylecode="Rrule">9%</td>
                                 <td stylecode="Rrule">12%</td>
                                 <td stylecode="Rrule">17%</td>
                                 <td stylecode="Rrule">12%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Neutropenia</td>
                                 <td stylecode="Rrule">0%</td>
                                 <td stylecode="Rrule">&lt;1%</td>
                                 <td stylecode="Rrule">&lt;1%</td>
                                 <td stylecode="Rrule">12%</td>
                                 <td stylecode="Rrule">17%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Myalgia</td>
                                 <td stylecode="Rrule">0%</td>
                                 <td stylecode="Rrule">6%</td>
                                 <td stylecode="Rrule">9%</td>
                                 <td stylecode="Rrule">16%</td>
                                 <td stylecode="Rrule">14%</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Irritability</td>
                                 <td stylecode="Rrule">1%</td>
                                 <td stylecode="Rrule">10%</td>
                                 <td stylecode="Rrule">10%</td>
                                 <td stylecode="Rrule">16%</td>
                                 <td stylecode="Rrule">13%</td>
                              </tr>
                           </tbody>
                        </table>
                        <p>With the exception of anemia and neutropenia, the majority of events presented in Table 2 occurred at severity of grade 1 in SOVALDI-containing regimens.</p>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="bold italics">Less Common Adverse Reactions Reported in Clinical Trials (less than 1%): </content> The following adverse reactions occurred in less than 1% of subjects receiving SOVALDI in a combination regimen in any one trial. These events have been included because of their seriousness or assessment of potential causal relationship.</p>
                              <p>
                                 <content stylecode="italics">Hematologic Effects: </content> pancytopenia (particularly in subjects receiving concomitant pegylated interferon).</p>
                              <p>
                                 <content stylecode="italics">Psychiatric Disorders: </content> severe depression (particularly in subjects with pre-existing history of psychiatric illness), including suicidal ideation and suicide.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Bilirubin Elevations</content>
                              </p>
                              <p>Total bilirubin elevation of more than 2.5×ULN was observed in none of the subjects in the SOVALDI + peginterferon alfa + ribavirin 12 weeks group and in 1%, 3% and 3% of subjects in the peginterferon alfa + ribavirin 24 weeks, SOVALDI + ribavirin 12 weeks and SOVALDI + ribavirin 24 weeks groups, respectively. Bilirubin levels peaked during the first 1 to 2 weeks of treatment and subsequently decreased and returned to baseline levels by post-treatment Week 4. These bilirubin elevations were not associated with transaminase elevations.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Creatine Kinase Elevations</content>
                              </p>
                              <p>Creatine kinase was assessed in the FISSION and NEUTRINO trials. Isolated, asymptomatic creatine kinase elevation of greater than or equal to 10×ULN was observed in less than 1%, 1% and 2% of subjects in the peginterferon alfa + ribavirin 24 weeks, SOVALDI + peginterferon alfa + ribavirin 12 weeks and SOVALDI + ribavirin 12 weeks groups, respectively.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Lipase Elevations</content>
                              </p>
                              <p>Isolated, asymptomatic lipase elevation of greater than 3×ULN was observed in less than 1%, 2%, 2%, and 2% of subjects in the SOVALDI + peginterferon alfa + ribavirin 12 weeks, SOVALDI + ribavirin 12 weeks, SOVALDI + ribavirin 24 weeks and peginterferon alfa + ribavirin 24 weeks groups, respectively.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Patients with HCV/HIV-1 Co-infection</content>
                              </p>
                              <p>SOVALDI used in combination with ribavirin was assessed in 223 HCV/HIV-1 co-infected subjects <content stylecode="italics">[see <a href="#S14.4">Clinical Studies (14.4)</a>]</content>. The safety profile in HCV/HIV-1 co-infected subjects was similar to that observed in HCV mono-infected subjects. Elevated total bilirubin (grade 3 or 4) was observed in 30/32 (94%) subjects receiving atazanavir as part of the antiretroviral regimen. None of the subjects had concomitant transaminase increases. Among subjects not taking atazanavir, grade 3 or 4 elevated total bilirubin was observed in 2 (1.5%) subjects, similar to the rate observed with HCV mono-infected subjects receiving SOVALDI + ribavirin in Phase 3 trials.</p>
                           </text></div>
<span id="SOVALDI_collapsableElement_6_2" class="safetySubheading">6.2	Postmarketing Experience</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The following adverse reactions have been identified during post approval use of SOVALDI. Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Cardiac Disorders</content>
                              </p>
                              <p>Serious symptomatic bradycardia has been reported in patients taking amiodarone who initiate treatment with SOVALDI in combination with another HCV direct acting antiviral <content stylecode="italics"> [see <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S7.1">Drug Interactions (7.1)</a>].</content>
                              </p>
                           </text></div>
</div>
</div>
<div class="section riskhide">
<div id="nonCollapsableElement_34073-7">
<div class="drugSubheadings">
<span id="SOVALDI_34073-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>7	DRUG INTERACTIONS</div>
<div id="SOVALDI_previewText_34073-7" class="previewText">
                        
                           Coadministration of amiodar<span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34073-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>Coadministration of amiodarone with SOVALDI in combination with another DAA may result in serious symptomatic bradycardia. (<a href="#S5.1">5.1</a>, <a href="#S6.2">6.2</a>, <a href="#S7.1">7.1</a>)</li>
                           <li>Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John's wort) may alter the concentrations of sofosbuvir. (<a href="#S5.2">5.2</a>, <a href="#S7">7</a>, <a href="#S12.3">12.3</a>)</li>
                           <li>Consult the full prescribing information prior to use for potential drug-drug interactions. (<a href="#S5.1">5.1</a>, <a href="#S5.2">5.2</a>, <a href="#S7">7</a>, <a href="#S12.3">12.3</a>)</li>
                        </ul>
                     </text></div>
<span id="SOVALDI_collapsableElement_7_1" class="safetySubheading">7.1	Potentially Significant Drug Interactions</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Sofosbuvir is a substrate of drug transporter P-gp and breast cancer resistance protein (BCRP) while the predominant circulating metabolite GS-331007 is not. Drugs that are P-gp inducers in the intestine (e.g., rifampin or St. John's wort) may decrease sofosbuvir plasma concentration, leading to reduced therapeutic effect of SOVALDI, and thus concomitant use with SOVALDI is not recommended <content stylecode="italics"> [see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</content>.</p>
                        <p>Information on potential drug interactions with SOVALDI is summarized in Table 4. The table is not all-inclusive <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.2">5.2)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</content>
                        </p>
                        <table width="75%" id="table4">
                           <caption>Table 4	Potentially Significant Drug Interactions: Alteration in Dosage or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction<footnote id="t4f1">This table is not all-inclusive.</footnote>
                           </caption>
                           <colgroup><col width="25%" align="left" valign="top">
                           <col width="25%" align="left" valign="top">
                           <col width="50%" align="left" valign="top">
                           </colgroup><thead>
                              <tr>
                                 <th align="center" stylecode="Lrule Rrule">Concomitant Drug Class: Drug Name</th>
                                 <th align="center" stylecode="Rrule" valign="middle">Effect on Concentration<footnote id="t4f2">↓ = decrease.</footnote>
                                 </th>
                                 <th align="center" stylecode="Rrule" valign="middle">Clinical Comment</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Antiarrhythmics:</content>
                                    <br>amiodarone</td>
                                 <td stylecode="Rrule">Effect on amiodarone and sofosbuvir  concentrations unknown</td>
                                 <td stylecode="Rrule">Coadministration of amiodarone with SOVALDI in combination with another DAA may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. Coadministration of amiodarone with SOVALDI in combination with another DAA is not recommended; if coadministration is required, cardiac monitoring is recommended <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S6.2">Adverse Reactions (6.2)</a>].</content>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Anticonvulsants:</content>
                                    <br>carbamazepine<br>phenytoin<br>phenobarbital<br>oxcarbazepine</td>
                                 <td stylecode="Rrule">↓ sofosbuvir<br>↓ GS-331007</td>
                                 <td stylecode="Rrule">Coadministration of SOVALDI with carbamazepine, phenytoin, phenobarbital or oxcarbazepine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI. Coadministration is not recommended.</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Antimycobacterials:</content>
                                    <br>rifabutin<br>rifampin<br>rifapentine</td>
                                 <td stylecode="Rrule">↓ sofosbuvir<br>↓ GS-331007</td>
                                 <td stylecode="Rrule">Coadministration of SOVALDI with rifabutin or rifapentine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI. Coadministration is not recommended.<br>Coadministration of SOVALDI with rifampin, an intestinal P-gp inducer, is not recommended <content stylecode="italics"> [see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</content>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Herbal Supplements:</content>
                                    <br>St. John's wort <content stylecode="italics">(Hypericum perforatum)</content>
                                 </td>
                                 <td stylecode="Rrule">↓ sofosbuvir<br>↓ GS-331007</td>
                                 <td stylecode="Rrule">Coadministration of SOVALDI with St. John's wort, an intestinal P-gp inducer, is not recommended <content stylecode="italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">HIV Protease Inhibitors:</content>
                                    <br>tipranavir/ritonavir</td>
                                 <td stylecode="Rrule">↓ sofosbuvir<br>↓ GS-331007</td>
                                 <td stylecode="Rrule">Coadministration of SOVALDI with tipranavir/ritonavir is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI.  Coadministration is not recommended.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="SOVALDI_collapsableElement_7_2" class="safetySubheading">7.2	Drugs without Clinically Significant Interactions with SOVALDI</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>In addition to the drugs included in Table 4, the interaction between SOVALDI and the following drugs was evaluated in clinical trials and no dose adjustment is needed for either drug <content stylecode="italics"> [See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]: </content> cyclosporine, darunavir/ritonavir, efavirenz, emtricitabine, methadone, oral contraceptives, raltegravir, rilpivirine, tacrolimus, or tenofovir disoproxil fumarate.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43684-0">
<div class="drugSubheadings">
<span id="SOVALDI_43684-0" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>8 USE IN SPECIFIC POPULATIONS</div>
<div id="SOVALDI_previewText_43684-0" class="previewText">
                        
                           Patients with HCV/HIV-1 co-<span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_43684-0" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>Patients with HCV/HIV-1 co-infection: Safety and efficacy have been studied. (<a href="#S14.4">14.4</a>)</li>
                           <li>Patients with hepatocellular carcinoma awaiting liver transplantation: Safety and efficacy have been studied. (<a href="#S8.8">8.8</a>)</li>
                        </ul>
                     </text></div>
<span id="SOVALDI_collapsableElement_8_1" class="safetySubheading">8.1 Pregnancy</span><div id="42228-7" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Pregnancy Category B:</content>
                              </p>
                              <p>There are no adequate and well-controlled studies with SOVALDI in pregnant women. Because animal reproduction studies are not always predictive of human response, SOVALDI should be used during pregnancy only if the potential for benefit justifies the potential risk to the fetus.</p>
                              <p>If SOVALDI is administered with ribavirin or peginterferon and ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. Refer to the ribavirin and/or peginterferon prescribing information for more information on use in males and females of child-bearing potential.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Animal Data</content>
                              </p>
                              <p>No effects on fetal development have been observed in rats and rabbits at the highest doses tested. In the rat and rabbit, AUC exposure to the predominant circulating metabolite GS-331007 increased over the course of gestation from approximately 5- to 10-fold and 12- to 28-fold the exposure in humans at the recommended clinical dose, respectively.</p>
                           </text></div>
<span id="SOVALDI_collapsableElement_8_3" class="safetySubheading">8.3	Nursing Mothers</span><div id="34080-2" class="safetySubdescription"><text>
                        <p>It is not known whether SOVALDI and its metabolites are present in human breast milk. The predominant circulating metabolite GS-331007 was the primary component observed in the milk of lactating rats, without effect on nursing pups. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SOVALDI and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.</p>
                        <p>If SOVALDI is administered in a regimen containing ribavirin, the information for ribavirin with regard to nursing mothers also applies to this combination regimen. Refer to the ribavirin prescribing information for more information on use in nursing mothers.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_8_4" class="safetySubheading">8.4	Pediatric Use</span><div id="34081-0" class="safetySubdescription"><text>
                        <p>Safety and effectiveness of SOVALDI in children less than 18 years of age have not been established.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_8_5" class="safetySubheading">8.5	Geriatric Use</span><div id="34082-8" class="safetySubdescription"><text>
                        <p>SOVALDI was administered to 90 subjects aged 65 and over. The response rates observed for subjects over 65 years of age were similar to that of younger subjects across treatment groups<content stylecode="bold">. </content> No dosage adjustment of SOVALDI is warranted in geriatric patients <content stylecode="italics"> [see <a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</content>.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_8_6" class="safetySubheading">8.6	Renal Impairment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>No dosage adjustment of SOVALDI is required for patients with mild or moderate renal impairment. The safety and efficacy of SOVALDI have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m<sup>2</sup>) or ESRD requiring hemodialysis. No dosage recommendation can be given for patients with severe renal impairment or ESRD <content stylecode="italics"> [see <a href="#S2.4"> Dosage and Administration (2.4)</a> and <a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</content>. Refer also to ribavirin and peginterferon alfa prescribing information for patients with CrCl less than 50 mL/min.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_8_7" class="safetySubheading">8.7	Hepatic Impairment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>No dosage adjustment of SOVALDI is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C) <content stylecode="italics"> [see <a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</content>. Safety and efficacy of SOVALDI have not been established in patients with decompensated cirrhosis<content stylecode="italics">.</content> See peginterferon alfa prescribing information for contraindication in hepatic decompensation.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_8_8" class="safetySubheading">8.8	Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>SOVALDI was studied in HCV-infected subjects with hepatocellular carcinoma prior to undergoing liver transplantation in an open-label clinical trial evaluating the safety and efficacy of SOVALDI and ribavirin administered pre-transplant to prevent post-transplant HCV reinfection. The primary endpoint of the trial was post-transplant virologic response (pTVR) defined as HCV RNA less than lower limit of quantification (LLOQ) at 12 weeks post-transplant.  HCV-infected subjects, regardless of genotype, with hepatocellular carcinoma (HCC) meeting the MILAN criteria (defined as the presence of a tumor 5 cm or less in diameter in patients with single hepatocellular carcinomas and no more than three tumor nodules, each 3 cm or less in diameter in patients with multiple tumors and no extrahepatic manifestations of the cancer or evidence of vascular invasion of tumor) received 400 mg SOVALDI and weight-based 1000–1200 mg ribavirin daily for 24–48 weeks or until the time of liver transplantation, whichever occurred first. An interim analysis was conducted on 61 subjects who received SOVALDI and ribavirin; 45 subjects had HCV genotype 1; 44 subjects had a baseline CPT score less than 7 and all subjects had a baseline unadjusted MELD score up to 14. Of these 61 subjects, 41 subjects underwent liver transplantation following up to 48 weeks of treatment with SOVALDI and ribavirin; 37 had HCV RNA less than LLOQ at the time of transplantation. Of the 37 subjects, the post-transplant virologic response (pTVR) rate is 64% (23/36) in the 36 evaluable subjects who have reached the 12 week post-transplant time point. The safety profile of SOVALDI and ribavirin in HCV-infected subjects prior to liver transplantation was comparable to that observed in subjects treated with SOVALDI and ribavirin in Phase 3 clinical trials.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_8_9" class="safetySubheading">8.9	Post-Liver Transplant Patients</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The safety and efficacy of SOVALDI have not been established in post-liver transplant patients.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_8_10" class="safetySubheading">8.10 	Patients with Genotype 5 or 6 HCV Infection</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Available data on subjects with genotype 5 or 6 HCV infection are insufficient for dosing recommendations.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34088-5">
<div class="drugSubheadings">
<span id="SOVALDI_34088-5" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>10	OVERDOSAGE</div>
<div id="SOVALDI_previewText_34088-5" class="previewText">
                  The highest documented dosage of sofosbuvir was a single dose<span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34088-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>The highest documented dosage of sofosbuvir was a single dose of sofosbuvir 1200 mg (three times the recommended dosage) administered to 59 healthy subjects. In that trial, there were no untoward effects observed at this dosage level, and adverse events were similar in frequency and severity to those reported in the placebo and sofosbuvir 400 mg treatment groups. The effects of higher dosages are not known.</p>
                  <p>No specific antidote is available for overdose with SOVALDI. If overdose occurs, the patient must be monitored for evidence of toxicity. Treatment of overdose with SOVALDI consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. A 4-hour hemodialysis session removed 18% of the administered dose.</p>
               </text></div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34089-3">
<div class="drugSubheadings">
<span id="SOVALDI_34089-3" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>11	DESCRIPTION </div>
<div id="SOVALDI_previewText_34089-3" class="previewText">
                  SOVALDI (sofosbuvir) is a nucleotide analog inhibitor of HCV <span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34089-3" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p>SOVALDI (sofosbuvir) is a nucleotide analog inhibitor of HCV NS5B polymerase.</p>
                  <p>The IUPAC name for sofosbuvir is (<content stylecode="italics">S</content>)-Isopropyl 2-((<content stylecode="italics">S</content>)-(((2<content stylecode="italics">R</content>,3<content stylecode="italics">R</content>,4<content stylecode="italics">R</content>,5<content stylecode="italics">R</content>)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2<content stylecode="italics">H</content>)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate. It has a molecular formula of C<sub>22</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>9</sub>P and a molecular weight of 529.45.  It has the following structural formula:</p>
                  <p>
                     <rendermultimedia referencedobject="MM1"></rendermultimedia>
                  </p>
                  <p>Sofosbuvir is a white to off-white crystalline solid with a solubility of ≥ 2 mg/mL across the pH range of 2–7.7 at 37 °C and is slightly soluble in water.</p>
                  <p>SOVALDI tablets are for oral administration.  Each tablet contains 400 mg of sofosbuvir. The tablets include the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, and microcrystalline cellulose. The tablets are film-coated with a coating material containing the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.</p>
               </text></div>
<span id="SOVALDI_collapsableElement_" class="safetySubheading"></span><div id="" class="safetySubdescription"></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34090-1">
<div class="drugSubheadings">
<span id="SOVALDI_34090-1" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>12	CLINICAL PHARMACOLOGY</div>
<div id="SOVALDI_previewText_34090-1" class="previewText"><span>...</span></div>
</div>
<div id="SOVALDI_collapsableElement_34090-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="SOVALDI_collapsableElement_12_1" class="safetySubheading">12.1	Mechanism of Action</span><div id="43679-0" class="safetySubdescription"><text>
                        <p>Sofosbuvir is a direct-acting antiviral agent against the hepatitis C virus <content stylecode="italics"> [see <a href="#S12.4">Microbiology (12.4)</a>].</content>
                        </p>
                     </text></div>
<span id="SOVALDI_collapsableElement_12_2" class="safetySubheading">12.2	Pharmacodynamics</span><div id="43681-6" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Cardiac Electrophysiology</content>
                              </p>
                              <p>The effect of sofosbuvir 400 and 1200 mg (three times the recommended dosage) on QTc interval was evaluated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg) four period crossover thorough QT trial in 59 healthy subjects. At a dosage three times the maximum recommended dosage, SOVALDI does not prolong QTc to any clinically relevant extent.</p>
                           </text></div>
<span id="SOVALDI_collapsableElement_12_3" class="safetySubheading">12.3 Pharmacokinetics</span><div id="43682-4" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Absorption</content>
                              </p>
                              <p>The pharmacokinetic properties of sofosbuvir and the predominant circulating metabolite GS-331007 have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C.  Following oral administration of SOVALDI, sofosbuvir was absorbed with a peak plasma concentration observed at ~0.5–2 hour post-dose, regardless of dose level. Peak plasma concentration of GS-331007 was observed between 2 to 4 hours post-dose. Based on population pharmacokinetic analysis in subjects with genotype 1 to 6 HCV infection who were coadministered ribavirin (with or without pegylated interferon), geometric mean steady state AUC<sub>0–24</sub> was 969 ng∙hr/mL for sofosbuvir (N=838), and 6790 ng∙hr/mL for GS-331007 (N=1695). Relative to healthy subjects administered sofosbuvir alone (N=272), the sofosbuvir AUC<sub>0–24 </sub>was 60% higher; and GS-331007 AUC<sub>0–24 </sub>was 39% lower, respectively, in HCV-infected subjects. Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 1200 mg.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Effect of Food</content>
                              </p>
                              <p>Relative to fasting conditions, the administration of a single dose of SOVALDI with a standardized high fat meal did not substantially affect the sofosbuvir C<sub>max</sub> or AUC<sub>0–inf</sub>. The exposure of GS-331007 was not altered in the presence of a high-fat meal. Therefore, SOVALDI can be administered without regard to food.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Distribution</content>
                              </p>
                              <p>Sofosbuvir is approximately 61–65% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1 microgram/mL to 20 microgram/mL. Protein binding of GS-331007 was minimal in human plasma. After a single 400 mg dose of [<sup>14</sup>C]-sofosbuvir in healthy subjects, the blood to plasma ratio of <sup>14</sup>C-radioactivity was approximately 0.7.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Metabolism </content>
                              </p>
                              <p>Sofosbuvir is extensively metabolized in the liver to form the pharmacologically active nucleoside analog triphosphate GS-461203. The metabolic activation pathway involves sequential hydrolysis of the carboxyl ester moiety catalyzed by human cathepsin A (CatA) or carboxylesterase 1 (CES1) and phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 (HINT1) followed by phosphorylation by the pyrimidine nucleotide biosynthesis pathway. Dephosphorylation results in the formation of nucleoside metabolite GS-331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity <content stylecode="italics"> in vitro</content>.</p>
                              <p>After a single 400 mg oral dose of [<sup>14</sup>C]-sofosbuvir, sofosbuvir and GS-331007 accounted for approximately 4% and greater than 90% of drug related material (sum of molecular weight-adjusted AUC of sofosbuvir and its metabolites) systemic exposure, respectively.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Elimination</content>
                              </p>
                              <p>Following a single 400 mg oral dose of [<sup>14</sup>C]-sofosbuvir, mean total recovery of the dose was greater than 92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, feces, and expired air, respectively. The majority of the sofosbuvir dose recovered in urine was GS-331007 (78%) while 3.5% was recovered as sofosbuvir. These data indicate that renal clearance is the major elimination pathway for GS-331007. The median terminal half-lives of sofosbuvir and GS-331007 were 0.4 and 27 hours, respectively.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="italics">Specific Populations</content>
                              </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Assessment of Drug Interactions</content>
                              </p>
                              <p>Sofosbuvir is a substrate of drug transporter P-gp and breast cancer resistance protein (BCRP) while GS-331007 is not. Drugs that are P-gp inducers in the intestine (e.g., rifampin or St. John's wort) may decrease sofosbuvir plasma concentration, leading to reduced therapeutic effect of SOVALDI, and thus concomitant use with SOVALDI is not recommended <content stylecode="italics">[see <a href="#S5.2">Warnings and Precautions (5.2) </a> and <a href="#S7.1"> Drug Interactions (7.1)</a>]</content>.</p>
                              <p>Coadministration of SOVALDI with drugs that inhibit P-gp and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma concentration; accordingly, SOVALDI may be coadministered with P-gp and/or BCRP inhibitors. Sofosbuvir and GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of drugs that are substrates of these transporters.</p>
                              <p>The intracellular metabolic activation pathway of sofosbuvir is mediated by generally low affinity and high capacity hydrolase and nucleotide phosphorylation pathways that are unlikely to be affected by concomitant drugs.</p>
                              <p>The effects of coadministered drugs on the exposure of sofosbuvir and GS-331007 are shown in Table 5. The effects of sofosbuvir on the exposure of coadministered drugs are shown in Table 6 <content stylecode="italics"> [see <a href="#S7.2">Drug Interactions (7.2)</a>].</content>
                              </p>
                              <table width="85%" id="table5">
                                 <caption>Table 5	Drug Interactions: Changes in Pharmacokinetic Parameters for Sofosbuvir and the Predominant Circulating Metabolite GS-331007 in the Presence of the Coadministered Drug<footnote id="t5f1">All interaction studies conducted in healthy volunteers</footnote>
                                 </caption>
                                 <colgroup><col width="13%" align="center" valign="middle">
                                 <col width="13%" align="center" valign="middle">
                                 <col width="13%" align="center" valign="middle">
                                 <col width="5%" align="center" valign="middle">
                                 <col width="10%" align="center" valign="middle">
                                 <col width="13%" align="center" valign="middle">
                                 <col width="13%" align="center" valign="middle">
                                 <col width="13%" align="center" valign="middle">
                                 <col width="7%" align="center" valign="middle">
                                 </colgroup><thead>
                                    <tr>
                                       <th rowspan="2" stylecode="Lrule Rrule">Co-administered Drug</th>
                                       <th rowspan="2" stylecode="Rrule">Dose of Coadministered Drug (mg)</th>
                                       <th rowspan="2" stylecode="Rrule">Sofosbuvir Dose (mg)</th>
                                       <th rowspan="2" stylecode="Rrule">N</th>
                                       <th colspan="4" stylecode="Rrule Botrule">Mean Ratio (90% CI) of Sofosbuvir and GS-331007 PK With/Without Coadministered Drug<br>No Effect=1.00</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Rrule"></th>
                                       <th stylecode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th stylecode="Rrule">AUC</th>
                                       <th stylecode="Rrule">C<sub>min</sub>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="9" align="left" valign="top">NA = not available/not applicable</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td rowspan="2" stylecode="Lrule Rrule">Cyclosporine</td>
                                       <td rowspan="2" stylecode="Rrule">600 single dose</td>
                                       <td rowspan="2" stylecode="Rrule">400 single dose</td>
                                       <td rowspan="2" stylecode="Rrule">19</td>
                                       <td stylecode="Rrule">sofosbuvir</td>
                                       <td stylecode="Rrule">2.54<br>(1.87, 3.45)</td>
                                       <td stylecode="Rrule">4.53<br>(3.26, 6.30)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">GS-331007</td>
                                       <td stylecode="Rrule">0.60<br> (0.53, 0.69)</td>
                                       <td stylecode="Rrule">1.04<br>(0.90, 1.20)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td rowspan="2" stylecode="Lrule Rrule">Darunavir<br>(boosted with ritonavir)</td>
                                       <td rowspan="2" stylecode="Rrule">800/100 once daily</td>
                                       <td rowspan="2" stylecode="Rrule">400 single dose</td>
                                       <td rowspan="2" stylecode="Rrule">18</td>
                                       <td stylecode="Rrule">sofosbuvir</td>
                                       <td stylecode="Rrule">1.45<br>(1.10, 1.92)</td>
                                       <td stylecode="Rrule">1.34<br>(1.12, 1.59)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">GS-331007</td>
                                       <td stylecode="Rrule">0.97<br>(0.90, 1.05)</td>
                                       <td stylecode="Rrule">1.24<br>(1.18, 1.30)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Efavirenz<footnote id="t5f3">Administered as efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed dose tablet</footnote>
                                       </td>
                                       <td stylecode="Rrule">600 once daily</td>
                                       <td rowspan="3" stylecode="Rrule">400 single dose<br>
                                       </td>
                                       <td rowspan="3" stylecode="Rrule">16</td>
                                       <td rowspan="2" stylecode="Rrule">sofosbuvir</td>
                                       <td rowspan="2" stylecode="Rrule">0.81<br>(0.60, 1.10)</td>
                                       <td rowspan="2" stylecode="Rrule">0.94<br>(0.76, 1.16)</td>
                                       <td rowspan="2" stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Emtricitabine<footnoteref idref="t5f3"></footnoteref>
                                       </td>
                                       <td stylecode="Rrule">200 once daily</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Tenofovir disoproxil fumarate<footnoteref idref="t5f3"></footnoteref>
                                       </td>
                                       <td stylecode="Rrule">300 once daily</td>
                                       <td stylecode="Rrule">GS-331007</td>
                                       <td stylecode="Rrule">0.77<br>(0.70, 0.84)</td>
                                       <td stylecode="Rrule">0.84<br>(0.76, 0.92)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td rowspan="2" stylecode="Lrule Rrule">Methadone</td>
                                       <td rowspan="2" stylecode="Rrule">30 to 130 once daily</td>
                                       <td rowspan="2" stylecode="Rrule">400 once daily</td>
                                       <td rowspan="2" stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">sofosbuvir</td>
                                       <td stylecode="Rrule">0.95<footnote id="t5f2">Comparison based on historic control</footnote>
                                          <br>(0.68, 1.33)</td>
                                       <td stylecode="Rrule">1.30<footnoteref idref="t5f2"></footnoteref>
                                          <br>(1.00, 1.69)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">GS-331007</td>
                                       <td stylecode="Rrule">0.73<footnoteref idref="t5f2"></footnoteref>
                                          <br>(0.65, 0.83)</td>
                                       <td stylecode="Rrule">1.04<footnoteref idref="t5f2"></footnoteref>
                                          <br>(0.89, 1.22)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td rowspan="2" stylecode="Lrule Rrule">Rilpivirine</td>
                                       <td rowspan="2" stylecode="Rrule">25 once daily</td>
                                       <td rowspan="2" stylecode="Rrule">400 single dose</td>
                                       <td rowspan="2" stylecode="Rrule">17</td>
                                       <td stylecode="Rrule">sofosbuvir</td>
                                       <td stylecode="Rrule">1.21<br>(0.90, 1.62)</td>
                                       <td stylecode="Rrule">1.09<br>(0.94, 1.27)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">GS-331007</td>
                                       <td stylecode="Rrule">1.06<br>(0.99, 1.14)</td>
                                       <td stylecode="Rrule">1.01<br>(0.97, 1.04)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td rowspan="2" stylecode="Lrule Rrule">Tacrolimus</td>
                                       <td rowspan="2" stylecode="Rrule">5 single dose</td>
                                       <td rowspan="2" stylecode="Rrule">400 single dose</td>
                                       <td rowspan="2" stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">sofosbuvir</td>
                                       <td stylecode="Rrule">0.97<br>(0.65, 1.43)</td>
                                       <td stylecode="Rrule">1.13<br>(0.81, 1.57)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Rrule">GS-331007</td>
                                       <td stylecode="Rrule">0.97<br>(0.83, 1.14)</td>
                                       <td stylecode="Rrule">1.00<br>(0.87, 1.13)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>No effect on the pharmacokinetic parameters of sofosbuvir and GS-331007 was observed with raltegravir.</p>
                              <table width="85%" id="table6">
                                 <caption>Table 6	Drug Interactions:  Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Sofosbuvir<footnote id="t6f1">All interaction studies conducted in healthy volunteers</footnote>
                                 </caption>
                                 <colgroup><col width="17%" valign="middle" align="center">
                                 <col width="17%" valign="middle" align="center">
                                 <col width="16%" valign="middle" align="center">
                                 <col width="5%" valign="middle" align="center">
                                 <col width="15%" valign="middle" align="center">
                                 <col width="15%" valign="middle" align="center">
                                 <col width="15%" valign="middle" align="center">
                                 </colgroup><thead>
                                    <tr>
                                       <th rowspan="2" stylecode="Lrule Rrule">Coadministered Drug</th>
                                       <th rowspan="2" stylecode="Rrule">Dose of Coadministered Drug (mg)</th>
                                       <th rowspan="2" stylecode="Rrule">Sofosbuvir Dose (mg)</th>
                                       <th rowspan="2" stylecode="Rrule">N</th>
                                       <th colspan="3" stylecode="Rrule Botrule">Mean Ratio (90% CI) of Coadministered Drug PK With/Without Sofosbuvir<br>No Effect=1.00</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th stylecode="Rrule">AUC</th>
                                       <th stylecode="Rrule">C<sub>min</sub>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="7" valign="top">NA = not available/not applicable</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Norelgestromin</td>
                                       <td rowspan="3" stylecode="Rrule">norgestimate 0.18/0.215/0.25/ ethinyl estradiol 0.025 once daily</td>
                                       <td rowspan="3" stylecode="Rrule">400 once daily</td>
                                       <td rowspan="3" stylecode="Rrule">15</td>
                                       <td stylecode="Rrule">1.07<br>(0.94, 1.22)</td>
                                       <td stylecode="Rrule">1.06<br>(0.92, 1.21)</td>
                                       <td stylecode="Rrule">1.07<br>(0.89, 1.28)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Norgestrel</td>
                                       <td stylecode="Rrule">1.18<br>(0.99, 1.41)</td>
                                       <td stylecode="Rrule">1.19<br>(0.98, 1.45)</td>
                                       <td stylecode="Rrule">1.23<br>(1.00, 1.51)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Ethinyl estradiol</td>
                                       <td stylecode="Rrule">1.15<br>(0.97, 1.36)</td>
                                       <td stylecode="Rrule">1.09<br>(0.94, 1.26)</td>
                                       <td stylecode="Rrule">0.99<br>(0.80, 1.23)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Raltegravir</td>
                                       <td stylecode="Rrule">400 twice daily</td>
                                       <td stylecode="Rrule">400 single dose</td>
                                       <td stylecode="Rrule">19</td>
                                       <td stylecode="Rrule">0.57<br>(0.44, 0.75)</td>
                                       <td stylecode="Rrule">0.73<br>(0.59, 0.91)</td>
                                       <td stylecode="Rrule">0.95<br>(0.81, 1.12)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Tacrolimus</td>
                                       <td stylecode="Rrule">5 single dose</td>
                                       <td stylecode="Rrule">400 single dose</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">0.73<br>(0.59, 0.90)</td>
                                       <td stylecode="Rrule">1.09<br>(0.84, 1.40)</td>
                                       <td stylecode="Rrule">NA</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">Tenofovir disoproxil fumarate<footnote id="t6f2">Administered as efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed dose tablet</footnote>
                                       </td>
                                       <td stylecode="Rrule">300 once daily</td>
                                       <td stylecode="Rrule">400 single dose</td>
                                       <td stylecode="Rrule">16<br>
                                       </td>
                                       <td stylecode="Rrule">1.25<br>(1.08, 1.45)</td>
                                       <td stylecode="Rrule">0.98<br>(0.91, 1.05)</td>
                                       <td stylecode="Rrule">0.99<br>(0.91, 1.07)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>No effect on the pharmacokinetic parameters of the following coadministered drugs was observed with sofosbuvir: cyclosporine, darunavir/ritonavir, efavirenz, emtricitabine, methadone, or rilpivirine.</p>
                           </text></div>
<span id="SOVALDI_collapsableElement_12_4" class="safetySubheading">12.4 Microbiology</span><div id="49489-8" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Mechanism of Action</content>
                              </p>
                              <p>Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. In a biochemical assay, GS-461203 inhibited the polymerase activity of the recombinant NS5B from HCV genotype 1b, 2a, 3a and 4a with IC<sub>50</sub> values ranging from 0.7 to 2.6 micromolar. GS-461203 is neither an inhibitor of human DNA and RNA polymerases nor an inhibitor of mitochondrial RNA polymerase.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Antiviral Activity</content>
                              </p>
                              <p>In HCV replicon assays, the EC<sub>50 </sub> values of sofosbuvir against full-length replicons from genotype 1a, 1b, 2a, 3a and 4a, and chimeric 1b replicons encoding NS5B from genotype 2b, 5a or 6a ranged from 0.014 to 0.11 micromolar. The median EC<sub>50 </sub> value of sofosbuvir against chimeric replicons encoding NS5B sequences from clinical isolates was 0.062 micromolar for genotype 1a (range 0.029–0.128 micromolar; N=67), 0.102 micromolar for genotype 1b (range 0.045–0.170 micromolar; N=29), 0.029 micromolar for genotype 2 (range 0.014–0.081 micromolar; N=15) and 0.081 micromolar for genotype 3a (range 0.024–0.181 micromolar; N=106). In infectious virus assays, the EC<sub>50 </sub> values of sofosbuvir against genotype 1a and 2a were 0.03 and 0.02 micromolar, respectively. The presence of 40% human serum had no effect on the anti-HCV activity of sofosbuvir. Evaluation of sofosbuvir in combination with interferon alpha or ribavirin showed no antagonistic effect in reducing HCV RNA levels in replicon cells.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Resistance</content>
                              </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Cross Resistance</content>
                              </p>
                              <p>HCV replicons expressing the sofosbuvir-associated resistance substitution S282T were susceptible to NS5A inhibitors and ribavirin. HCV replicons expressing the ribavirin-associated substitutions T390I and F415Y were susceptible to sofosbuvir. Sofosbuvir was active against HCV replicons with NS3/4A protease inhibitor, NS5B non-nucleoside inhibitor and NS5A inhibitor resistant variants.</p>
                           </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43680-8">
<div class="drugSubheadings">
<span id="SOVALDI_43680-8" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>13 NONCLINICAL TOXICOLOGY</div>
<div id="SOVALDI_previewText_43680-8" class="previewText"><span>...</span></div>
</div>
<div id="SOVALDI_collapsableElement_43680-8" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="SOVALDI_collapsableElement_13_1" class="safetySubheading">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</span><div id="34083-6" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Carcinogenesis and Mutagenesis</content>
                              </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Impairment of Fertility</content>
                              </p>
                           </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34092-7">
<div class="drugSubheadings">
<span id="SOVALDI_34092-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>14 CLINICAL STUDIES</div>
<div id="SOVALDI_previewText_34092-7" class="previewText"><span>...</span></div>
</div>
<div id="SOVALDI_collapsableElement_34092-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="SOVALDI_collapsableElement_14_1" class="safetySubheading">14.1	Description of Clinical Trials</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The safety and efficacy of SOVALDI was evaluated in five Phase 3 trials in a total of 1724 HCV mono-infected subjects with genotypes 1 to 6 chronic hepatitis C virus and one Phase 3 trial in 223 HCV/HIV-1 co-infected subjects with genotype 1, 2 or 3 HCV, as summarized in Table 7.</p>
                        <table id="table7" width="85%">
                           <caption>Table 7	Trials Conducted with SOVALDI with Peginterferon Alfa and/or Ribavirin in Subjects with Chronic HCV Genotype 1, 2, 3, or 4 Infection</caption>
                           <colgroup><col width="28%" align="center" valign="middle">
                           <col width="32%" align="left" valign="middle">
                           <col width="40%" align="center" valign="middle">
                           </colgroup><thead>
                              <tr>
                                 <th stylecode="Lrule Rrule" valign="bottom">Trial</th>
                                 <th stylecode="Rrule" valign="bottom" align="center">Population</th>
                                 <th stylecode="Rrule" valign="bottom">Study Arms (Number of Subjects Treated)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">NEUTRINO</td>
                                 <td stylecode="Rrule">Treatment naïve (TN) (GT1, 4, 5 or 6)</td>
                                 <td stylecode="Rrule">SOVALDI+Peg-IFN alfa+RBV 12 weeks (327)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">FISSION</td>
                                 <td stylecode="Rrule">TN (GT2 or 3)</td>
                                 <td stylecode="Rrule">SOVALDI+RBV 12 Weeks (256)<br>Peg-IFN alfa+RBV 24 weeks (243)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">POSITRON</td>
                                 <td stylecode="Rrule">Interferon intolerant, ineligible or unwilling subjects (GT2 or 3)</td>
                                 <td stylecode="Rrule">SOVALDI+RBV 12 Weeks (207)<br>Placebo 12 weeks (71)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">FUSION</td>
                                 <td stylecode="Rrule">Previous interferon relapsers or nonresponders (GT2 or 3)</td>
                                 <td stylecode="Rrule">SOVALDI+RBV 12 Weeks (103)<br>SOVALDI+RBV 16 Weeks (98)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">VALENCE</td>
                                 <td stylecode="Rrule">TN or previous interferon relapsers or nonresponders (GT2 or 3)</td>
                                 <td stylecode="Rrule">SOVALDI+RBV 12 Weeks for GT2 (73)<br>SOVALDI+RBV 12 Weeks for GT3 (11)<br>SOVALDI+RBV 24 Weeks for GT3 (250)<br>Placebo for 12 weeks (85)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">PHOTON-1</td>
                                 <td stylecode="Rrule">
                                    <ul ultype="unordered">
                                       <li>HCV/HIV-1 co-infected TN (GT1)</li>
                                       <li>HCV/HIV-1 co-infected TN or previous interferon relapsers or nonresponders (GT2 or 3)</li>
                                    </ul>
                                 </td>
                                 <td stylecode="Rrule">SOVALDI+RBV 24 Weeks for GT1 (114)<br>SOVALDI+RBV 12 Weeks for GT2 or 3 TN (68)<br>SOVALDI+RBV 24 Weeks for GT2 or 3 previous interferon relapsers or nonresponders (41)</td>
                              </tr>
                           </tbody>
                        </table>
                        <p>Subjects in these trials had compensated liver disease including cirrhosis. SOVALDI was administered at a dose of 400 mg once daily. The ribavirin (RBV) dosage was weight-based at 1000–1200 mg daily administered in two divided doses when used in combination with SOVALDI, and the peginterferon alfa 2a dosage, where applicable, was 180 micrograms per week. Treatment duration was fixed in each trial and was not guided by subjects' HCV RNA levels (no response guided algorithm). Plasma HCV RNA values were measured during the clinical trials using the COBAS TaqMan HCV test (version 2.0), for use with the High Pure System. The assay had a lower limit of quantification (LLOQ) of 25 IU per mL. Sustained virologic response (SVR12) was the primary endpoint which was defined as HCV RNA less than LLOQ at 12 weeks after the end of treatment.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_14_2" class="safetySubheading">14.2	Clinical Trials in Subjects with Genotype 1 or 4 HCV</span><div id="42229-5" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Treatment-Naïve Adults ─ NEUTRINO (Study 110)</content>
                              </p>
                              <p>NEUTRINO was an open-label, single-arm trial that evaluated 12 weeks of treatment with SOVALDI in combination with peginterferon alfa 2a and ribavirin in treatment-naïve subjects with genotype 1, 4, 5 or 6 HCV infection compared to pre-specified historical control.</p>
                              <p>Treated subjects (N=327) had a median age of 54 years (range: 19 to 70); 64% of the subjects were male; 79% were White, 17% were Black; 14% were Hispanic or Latino; mean body mass index was 29 kg/m<sup>2</sup> (range: 18 to 56 kg/m<sup>2</sup>); 78% had baseline HCV RNA greater than 6 log<sub>10</sub> IU per mL; 17% had cirrhosis; 89% had HCV genotype 1; 9% had HCV genotype 4 and 2% had HCV genotype 5 or 6. Table 8 presents the SVR12 for the treatment group of SOVALDI + peginterferon alfa + ribavirin in subjects with genotype 1 or 4 HCV. Available data on subjects with genotype 5 or 6 HCV treated with SOVALDI + peginterferon alfa + ribavirin for 12 weeks were insufficient for dosing recommendations; therefore these results are not presented in Table 8 <content stylecode="italics">[see <a href="#S8.10">Use in Specific Populations (8.10)</a>]</content>.</p>
                              <table width="75%" id="table8">
                                 <caption>Table 8	Study NEUTRINO: SVR12 for Treatment-Naïve Subjects with Genotype 1 or 4 HCV</caption>
                                 <colgroup><col width="45%" align="left" valign="top">
                                 <col width="55%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">SOVALDI + Peg-IFN alfa + RBV 12 weeks</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=320</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Overall SVR</td>
                                       <td stylecode="Rrule">90% (289/320)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Genotype 1<footnote id="t8f1">One subject had genotype 1a/1b mixed infection.</footnote>
                                       </td>
                                       <td stylecode="Rrule">90% (262/292)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;&nbsp;&nbsp;Genotype 1a</td>
                                       <td stylecode="Rrule">92% (206/225)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;&nbsp;&nbsp;Genotype 1b</td>
                                       <td stylecode="Rrule">83% (55/66)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Genotype 4</td>
                                       <td stylecode="Rrule">96% (27/28)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Outcome for subjects without SVR</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;On-treatment virologic failure</td>
                                       <td stylecode="Rrule">0/320</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Relapse<footnote id="t8f2">The denominator for relapse is the number of subjects with HCV RNA &lt;LLOQ at their last on-treatment assessment.</footnote>
                                       </td>
                                       <td stylecode="Rrule">9% (28/319)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Other<footnote id="t8f3">Other includes subjects who did not achieve SVR and did not meet virologic failure criteria (e.g., lost to follow-up).</footnote>
                                       </td>
                                       <td stylecode="Rrule">1% (3/320)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>SVR12 for selected subgroups are presented in Table 9.</p>
                              <table width="75%" id="table9">
                                 <caption>Table 9	SVR12 Rates for Selected Subgroups in NEUTRINO in Subjects with Genotype 1 or 4 HCV</caption>
                                 <colgroup><col width="45%" align="left" valign="top">
                                 <col width="55%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">SOVALDI + Peg-IFN alfa  + RBV 12 weeks</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Cirrhosis</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;No</td>
                                       <td stylecode="Rrule">93% (247/267)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Yes</td>
                                       <td stylecode="Rrule">79% (42/53)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Race</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Black</td>
                                       <td stylecode="Rrule">87% (47/54)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Non-black</td>
                                       <td stylecode="Rrule">91% (242/266)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Multiple Baseline Factors</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Genotype 1, Metavir F3/F4 fibrosis, IL28B non-C/C, HCV RNA &gt;800,000 IU/mL</td>
                                       <td stylecode="Rrule" valign="middle">71% (37/52)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>SVR12 rates were 99% (89/90) in subjects with genotype 1 or 4 HCV and baseline IL28B C/C allele and 87% (200/230) in subjects with genotype 1 or 4 HCV and baseline IL28B non-C/C alleles.</p>
                              <p>It is estimated that the SVR12 in patients who previously failed pegylated interferon and ribavirin therapy will approximate the observed SVR12 in NEUTRINO subjects with multiple baseline factors traditionally associated with a lower response to interferon-based treatment (Table 9). The SVR12 rate in the NEUTRINO trial in genotype 1 subjects with IL28B non-C/C alleles, HCV RNA greater than 800,000 IU/mL and Metavir F3/F4 fibrosis was 71% (37/52).</p>
                           </text></div>
<span id="SOVALDI_collapsableElement_14_3" class="safetySubheading">14.3	Clinical Trials in Subjects with Genotype 2 or 3 HCV</span><div id="42229-5" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Treatment-Naïve Adults ─ FISSION (Study 1231)</content>
                              </p>
                              <p>FISSION was a randomized, open-label, active-controlled trial that evaluated 12 weeks of treatment with SOVALDI and ribavirin compared to 24 weeks of treatment with peginterferon alfa 2a and ribavirin in treatment-naïve subjects with genotype 2 and 3 HCV. The ribavirin dosage used in the SOVALDI + ribavirin and peginterferon alfa 2a + ribavirin arms were weight-based 1000–1200 mg per day and 800 mg per day regardless of weight, respectively. Subjects were randomized in a 1:1 ratio and stratified by cirrhosis (presence vs. absence), HCV genotype (2 vs. 3) and baseline HCV RNA level (less than 6 log<sub>10 </sub> IU/mL vs. at least 6 log<sub>10 </sub> IU/mL). Subjects with genotype 2 or 3 HCV were enrolled in an approximately 1:3 ratio.</p>
                              <p>Treated subjects (N=499) had a median age of 50 years (range: 19 to 77); 66% of the subjects were male; 87% were White, 3% were Black; 14% were Hispanic or Latino; mean body mass index was 28 kg/m<sup>2</sup> (range: 17 to 52 kg/m<sup>2</sup>); 57% had baseline HCV RNA levels greater than 6 log<sub>10 </sub> IU per mL; 20% had cirrhosis; 72% had HCV genotype 3.  Table 11 presents the SVR12 for the treatment groups of SOVALDI + ribavirin and peginterferon alfa + ribavirin in subjects with genotype 2 HCV. SVR12 for genotype 3 subjects treated with SOVALDI + ribavirin for 12 weeks was suboptimal; therefore these results are not presented in Table 10.</p>
                              <table width="85%" id="table10">
                                 <caption>Table 10	Study FISSION: SVR12 in Treatment-Naïve Subjects with Genotype 2 HCV</caption>
                                 <colgroup><col width="34%" align="left" valign="top">
                                 <col width="32%" align="center" valign="top">
                                 <col width="34%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">SOVALDI + RBV 12 weeks</th>
                                       <th stylecode="Rrule">Peg-IFN alfa + RBV 24 weeks</th>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=73<footnote id="t10f1">Including three subjects with recombinant genotype 2/1 HCV infection.</footnote>
                                       </th>
                                       <th stylecode="Rrule">N=67<footnoteref idref="t10f1"></footnoteref>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">SVR12</td>
                                       <td stylecode="Rrule">95% (69/73)</td>
                                       <td stylecode="Rrule">78% (52/67)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="3">Outcome for subjects without SVR12</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;On-treatment virologic failure</td>
                                       <td stylecode="Rrule">0/73</td>
                                       <td stylecode="Rrule">4% (3/67)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Relapse<footnote id="t10f2">The denominator for relapse is the number of subjects with HCV RNA &lt;LLOQ at their last on-treatment assessment.</footnote>
                                       </td>
                                       <td stylecode="Rrule">5% (4/73)</td>
                                       <td stylecode="Rrule">15% (9/62)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Other<footnote id="t10f3">Other includes subjects who did not achieve SVR and did not meet virologic failure criteria (e.g., lost to follow-up).</footnote>
                                       </td>
                                       <td stylecode="Rrule">0/73</td>
                                       <td stylecode="Rrule">4% (3/67)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>SVR12 for genotype 2 HCV infected subjects with cirrhosis at baseline are presented in Table 11.</p>
                              <table width="85%" id="table11">
                                 <caption>Table 11	SVR12 Rates by Cirrhosis in Study FISSION in Subjects with Genotype 2 HCV</caption>
                                 <colgroup><col width="32%" align="left" valign="top">
                                 <col width="34%" align="center" valign="top">
                                 <col width="34%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule" valign="middle">SOVALDI + RBV<br>12 weeks</th>
                                       <th stylecode="Rrule" valign="middle">Peg-IFN alfa + RBV<br>24 weeks</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=73</th>
                                       <th stylecode="Rrule">N=67</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td colspan="3" stylecode="Lrule Rrule">Cirrhosis</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" align="center">No</td>
                                       <td stylecode="Rrule">97% (59/61)</td>
                                       <td stylecode="Rrule">81% (44/54)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule" align="center">Yes</td>
                                       <td stylecode="Rrule">83% (10/12)</td>
                                       <td stylecode="Rrule">62% (8/13)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Interferon Intolerant, Ineligible or Unwilling Adults ─ POSITRON (Study 107)</content>
                              </p>
                              <p>POSITRON was a randomized, double-blinded, placebo-controlled trial that evaluated 12 weeks of treatment with SOVALDI and ribavirin (N=207) compared to placebo (N=71) in subjects who are interferon intolerant, ineligible or unwilling. Subjects were randomized in 3:1 ratio and stratified by cirrhosis (presence vs. absence).</p>
                              <p>Treated subjects (N=278) had a median age of 54 years (range: 21 to 75); 54% of the subjects were male; 91% were White, 5% were Black; 11% were Hispanic or Latino; mean body mass index was 28 kg/m<sup>2</sup> (range: 18 to 53 kg/m<sup>2</sup>); 70% had baseline HCV RNA levels greater than 6 log<sub>10</sub> IU per mL; 16% had cirrhosis; 49% had HCV genotype 3. The proportions of subjects who were interferon intolerant, ineligible, or unwilling were 9%, 44%, and 47%, respectively. Most subjects had no prior HCV treatment (81%). Table 13 presents the SVR12 for the treatment groups of SOVALDI + ribavirin and placebo in subjects with genotype 2 HCV. SVR12 for genotype 3 subjects treated with SOVALDI + ribavirin for 12 weeks was suboptimal; therefore these results are not presented in Table 12.</p>
                              <table width="75%" id="table12">
                                 <caption>Table 12	Study POSITRON: SVR12 in Interferon Intolerant, Ineligible or Unwilling Subjects with Genotype 2 HCV</caption>
                                 <colgroup><col width="34%" align="left" valign="top">
                                 <col width="32%" align="center" valign="top">
                                 <col width="34%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule Botrule">SOVALDI + RBV 12 weeks</th>
                                       <th stylecode="Rrule Botrule">Placebo 12 weeks</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=109</th>
                                       <th stylecode="Rrule">N= 34</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">SVR12</td>
                                       <td stylecode="Rrule">93% (101/109)</td>
                                       <td stylecode="Rrule">0/34</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td colspan="3" stylecode="Lrule Rrule">Outcome for subjects without SVR12</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;On-treatment virologic failure</td>
                                       <td stylecode="Rrule">0/109</td>
                                       <td stylecode="Rrule">97% (33/34)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Relapse<footnote id="t12f1">The denominator for relapse is the number of subjects with HCV RNA &lt;LLOQ at their last on-treatment assessment.</footnote>
                                       </td>
                                       <td stylecode="Rrule">5% (5/107)</td>
                                       <td stylecode="Rrule">0/0</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Other<footnote id="t12f2">Other includes subjects who did not achieve SVR and did not meet virologic failure criteria (e.g., lost to follow-up).</footnote>
                                       </td>
                                       <td stylecode="Rrule">3% (3/109)</td>
                                       <td stylecode="Rrule">3% (1/34)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>Table 13 presents the subgroup analysis for cirrhosis and interferon classification in subjects with genotype 2 HCV.</p>
                              <table width="75%" id="table13">
                                 <caption>Table 13	SVR12 Rates for Selected Subgroups in POSITRON in Subjects with Genotype 2 HCV</caption>
                                 <colgroup><col width="40%" align="left" valign="middle">
                                 <col width="60%" align="center" valign="middle">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">SOVALDI + RBV 12 weeks</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=109</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Cirrhosis</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;No</td>
                                       <td stylecode="Rrule">92% (85/92)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Yes</td>
                                       <td stylecode="Rrule">94% (16/17)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Interferon Classification</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Ineligible</td>
                                       <td stylecode="Rrule">88% (36/41)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Intolerant</td>
                                       <td stylecode="Rrule">100% (9/9)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Unwilling</td>
                                       <td stylecode="Rrule">95% (56/59)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Previously Treated Adults ─ FUSION (Study 108)</content>
                              </p>
                              <p>FUSION was a randomized, double-blinded trial that evaluated 12 or 16 weeks of treatment with SOVALDI and ribavirin in subjects who did not achieve SVR with prior interferon-based treatment (relapsers and nonresponders). Subjects were randomized in a 1:1 ratio and stratified by cirrhosis (presence vs. absence) and HCV genotype (2 vs. 3).</p>
                              <p>Treated subjects (N=201) had a median age of 56 years (range: 24 to 70); 70% of the subjects were male; 87% were White; 3% were Black; 9% were Hispanic or Latino; mean body mass index was 29 kg/m<sup>2</sup> (range: 19 to 44 kg/m<sup>2</sup>); 73% had baseline HCV RNA levels greater than 6 log<sub>10</sub> IU per mL; 34% had cirrhosis; 63% had HCV genotype 3; 75% were prior relapsers. Table 15 presents the SVR12 for the treatment groups of SOVALDI + ribavirin for 12 weeks in subjects with genotype 2 HCV. Treatment of 16 weeks in subjects with genotype 2 HCV was not shown to increase the SVR12 observed with 12 weeks of treatment.  SVR12 for genotype 3 subjects treated with SOVALDI + ribavirin for 12 or 16 weeks was suboptimal; therefore these results are not presented in Table 14.</p>
                              <table width="75%" id="table14">
                                 <caption>Table 14	Study FUSION: SVR12 in Previous Interferon Relapsers and Nonresponders with Genotype 2 HCV</caption>
                                 <colgroup><col width="52%" align="left" valign="top">
                                 <col width="48%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">SOVALDI +  RBV<br>12 weeks</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=39<footnote id="t14f1">Including three subjects with recombinant genotype 2/1 HCV infection.</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">SVR12</td>
                                       <td stylecode="Rrule">82% (32/39)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Outcome for subjects without SVR12</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;On-treatment virologic failure</td>
                                       <td stylecode="Rrule">0/39</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Relapse<footnote id="t14f2">The denominator for relapse is the number of subjects with HCV RNA &lt;LLOQ at their last on-treatment assessment.</footnote>
                                       </td>
                                       <td stylecode="Rrule">18% (7/39)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Other<footnote id="t14f3">Other includes subjects who did not achieve SVR and did not meet virologic failure criteria (e.g., lost to follow-up).</footnote>
                                       </td>
                                       <td stylecode="Rrule">0/39</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>Table 15 presents the subgroup analysis for cirrhosis and response to prior HCV treatment in subjects with genotype 2 HCV.</p>
                              <table width="75%" id="table15">
                                 <caption>Table 15 SVR12 Rates for Selected Subgroups in Study FUSION in Subjects
with Genotype 2 HCV</caption>
                                 <colgroup><col width="48%" align="left" valign="top">
                                 <col width="52%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">SOVALDI + RBV 12 weeks</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=39</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Cirrhosis</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;No</td>
                                       <td stylecode="Rrule">90% (26/29)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Yes</td>
                                       <td stylecode="Rrule">60% (6/10)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td colspan="2" stylecode="Lrule Rrule">Response to prior HCV treatment</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Relapser/  breakthrough</td>
                                       <td stylecode="Rrule">86% (25/29)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Nonresponder</td>
                                       <td stylecode="Rrule">70% (7/10)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Treatment-Naïve and Previously Treated Adults ─ VALENCE (Study 133)</content>
                              </p>
                              <p>The VALENCE trial evaluated SOVALDI in combination with weight-based ribavirin for the treatment of genotype 2 or 3 HCV infection in treatment-naïve subjects or subjects who did not achieve SVR with prior interferon-based treatment, including subjects with compensated cirrhosis. The original trial design was a 4 to 1 randomization to SOVALDI + ribavirin for 12 weeks or placebo. Based on emerging data, this trial was unblinded and all genotype 2 HCV-infected subjects continued the original planned treatment and received SOVALDI + ribavirin for 12 weeks, and duration of treatment with SOVALDI + ribavirin in genotype 3 HCV-infected subjects was extended to 24 weeks. Eleven genotype 3 subjects had already completed SOVALDI + ribavirin for 12 weeks at the time of the amendment.</p>
                              <p>Treated subjects (N=419) had a median age of 51 years (range: 19 to 74); 60% of the subjects were male; mean body mass index was 26 kg/m<sup>2 </sup> (range: 17 to 44 kg/m<sup>2</sup>); the mean baseline HCV RNA level was 6.4 log<sub>10 </sub>IU per mL; 78% had HCV genotype 3; 58% of the subjects were treatment-experienced and 65% of those subjects experienced relapse/breakthrough to prior HCV treatment.</p>
                              <p>Table 16 presents the SVR12 for the treatment groups of SOVALDI + ribavirin for 12 weeks and 24 weeks.</p>
                              <table width="75%" id="table16">
                                 <caption>Table 16	Study VALENCE<footnote id="t16f1">Placebo subjects (N=85) were not included as none achieved SVR12.</footnote>: SVR12 in Subjects with Genotype 2 or 3 HCV Who were Treatment-Naïve or Who Did Not Achieve SVR12 with Prior Interferon-Based Treatment</caption>
                                 <colgroup><col width="50%" align="left" valign="top">
                                 <col width="25%" align="center" valign="top">
                                 <col width="25%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">Genotype 2 SOVALDI + RBV 12 weeks</th>
                                       <th stylecode="Rrule">Genotype 3 SOVALDI + RBV 24 weeks</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=73</th>
                                       <th stylecode="Rrule">N=250</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Overall SVR</td>
                                       <td stylecode="Rrule">93% (68/73)</td>
                                       <td stylecode="Rrule">84% (210/250)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td colspan="3" stylecode="Lrule Rrule">Outcome for subjects without SVR</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;On-treatment virologic failure</td>
                                       <td stylecode="Rrule">0% (0/73)</td>
                                       <td stylecode="Rrule">&lt;1% (1/250)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Relapse<footnote id="t16f2">The denominator for relapse is the number of subjects with HCV RNA &lt;LLOQ at their last on-treatment
assessment.</footnote>
                                       </td>
                                       <td stylecode="Rrule">7% (5/73)</td>
                                       <td stylecode="Rrule">14% (34/249)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;&nbsp;&nbsp;Treatment-naïve</td>
                                       <td stylecode="Rrule">3% (1/32)</td>
                                       <td stylecode="Rrule">5% (5/105)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;&nbsp;&nbsp;Treatment-experienced</td>
                                       <td stylecode="Rrule">10% (4/41)</td>
                                       <td stylecode="Rrule">20% (29/144)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Other<footnote id="t16f3">Other includes subjects who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).</footnote>
                                       </td>
                                       <td stylecode="Rrule">0% (0/73)</td>
                                       <td stylecode="Rrule">2% (5/250)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>Table 17 presents the subgroup analysis by genotype for cirrhosis and prior HCV treatment experience.</p>
                              <table width="75%" id="table17">
                                 <caption>Table 17	SVR12 Rates for Selected Subgroups by Genotype in Study VALENCE in Subjects with Genotype 2 or 3 HCV</caption>
                                 <colgroup><col width="50%" align="left" valign="top">
                                 <col width="25%" align="center" valign="top">
                                 <col width="25%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">Genotype 2 SOVALDI + RBV 12 weeks</th>
                                       <th stylecode="Rrule">Genotype 3 SOVALDI + RBV 24 weeks</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">N=73</th>
                                       <th stylecode="Rrule">N=250</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Treatment-naïve</td>
                                       <td stylecode="Rrule">97% (31/32)</td>
                                       <td stylecode="Rrule">93% (98/105)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Non-cirrhotic</td>
                                       <td stylecode="Rrule">97% (29/30)</td>
                                       <td stylecode="Rrule">93% (86/92)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Cirrhotic</td>
                                       <td stylecode="Rrule">100% (2/2)</td>
                                       <td stylecode="Rrule">92% (12/13)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Treatment-experienced</td>
                                       <td stylecode="Rrule">90% (37/41)</td>
                                       <td stylecode="Rrule">77% (112/145)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Non-cirrhotic</td>
                                       <td stylecode="Rrule">91% (30/33)</td>
                                       <td stylecode="Rrule">85% (85/100)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">&nbsp;&nbsp;Cirrhotic</td>
                                       <td stylecode="Rrule">88% (7/8)</td>
                                       <td stylecode="Rrule">60% (27/45)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text></div>
<span id="SOVALDI_collapsableElement_14_4" class="safetySubheading">14.4	Clinical Trials in Subjects Co-infected with HCV and HIV-1</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>SOVALDI was studied in an open-label clinical trial (Study PHOTON-1) evaluating the safety and efficacy of 12 or 24 weeks of treatment with SOVALDI and ribavirin in subjects with genotype 1, 2 or 3 chronic hepatitis C co-infected with HIV-1. Genotype 2 and 3 subjects were either HCV treatment-naïve or experienced, whereas genotype 1 subjects were all treatment-naïve. Subjects received 400 mg SOVALDI and weight-based ribavirin (1000 mg for subjects weighing less than 75 kg or 1200 mg for subjects weighing at least 75 kg) daily for 12 or 24 weeks based on genotype and prior treatment history. Subjects were either not on antiretroviral therapy with a CD4+ cell count greater than 500 cells/mm<sup>3 </sup> or had virologically suppressed HIV-1 with a CD4+ cell count greater than 200 cells/mm<sup>3</sup>. Efficacy data 12 weeks post treatment are available for 210 subjects (see <a href="#table18">Table 18</a>).</p>
                        <table width="75%" id="table18">
                           <caption>Table 18	Study PHOTON-1<footnote id="t18f1">Subjects with genotype 2 HCV treated with SOVALDI + RBV for 24 weeks (N=15) and subjects with genotype 3 HCV treated with SOVALDI + RBV for 12 weeks (N=42) are not included in the table.</footnote>: SVR12 in Treatment-Naïve or Treatment-Experienced Subjects with Genotype 1, 2, or 3 HCV</caption>
                           <colgroup><col width="25%" align="left" valign="top">
                           <col width="25%" align="center" valign="top">
                           <col width="25%" align="center" valign="top">
                           <col width="25%" align="center" valign="top">
                           </colgroup><thead>
                              <tr stylecode="Botrule">
                                 <th stylecode="Lrule Rrule"></th>
                                 <th stylecode="Rrule">HCV genotype 1</th>
                                 <th stylecode="Rrule">HCV genotype 2</th>
                                 <th stylecode="Rrule">HCV genotype 3</th>
                              </tr>
                              <tr>
                                 <th stylecode="Lrule Rrule"></th>
                                 <th stylecode="Rrule">SOVALDI + RBV<br>24 weeks<br>TN (N=114)</th>
                                 <th stylecode="Rrule">SOVALDI + RBV<br>12 weeks<br>TN (N=26)</th>
                                 <th stylecode="Rrule">SOVALDI + RBV<br>24 weeks<br>TE (N=13)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left" valign="top">TN = Treatment-naïve; TE = Treatment-experienced</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Overall</td>
                                 <td stylecode="Rrule">76% (87/114)</td>
                                 <td stylecode="Rrule">88% (23/26)</td>
                                 <td stylecode="Rrule">92% (12/13)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td colspan="4" stylecode="Lrule Rrule">Outcome for subjects without SVR12</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;On-treatment virologic failure</td>
                                 <td stylecode="Rrule">1% (1/114)</td>
                                 <td stylecode="Rrule">4% (1/26)</td>
                                 <td stylecode="Rrule">0/13</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Relapse<footnote id="t18f2">The denominator for relapse is the number of subjects with HCV RNA &lt;LLOQ at their last on-treatment assessment.</footnote>
                                 </td>
                                 <td stylecode="Rrule">22% (25/113)</td>
                                 <td stylecode="Rrule">0/25</td>
                                 <td stylecode="Rrule">8% (1/13)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Other<footnote id="t18f3">Other includes subjects who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).</footnote>
                                 </td>
                                 <td stylecode="Rrule">1% (1/114)</td>
                                 <td stylecode="Rrule">8% (2/26)</td>
                                 <td stylecode="Rrule">0/13</td>
                              </tr>
                           </tbody>
                        </table>
                        <p>In subjects with HCV genotype 1 infection, the SVR12 rate was 82% (74/90) in subjects with genotype 1a infection and 54% (13/24) in subjects with genotype 1b infection, with relapse accounting for the majority of treatment failures. SVR12 rates in subjects with HCV genotype 1 infection were 80% (24/30) in subjects with baseline IL28B C/C allele and 75% (62/83) in subjects with baseline IL28B non-C/C alleles.</p>
                        <p>In the 223 HCV subjects with HIV-1 co-infection, the percentage of CD4+ cells did not change during treatment. Median CD4+ cell count decreases of 85 cells/mm<sup>3 </sup> and 84 cells/mm<sup>3 </sup> were observed at the end of treatment with SOVALDI + ribavirin for 12 or 24 weeks, respectively. HIV-1 rebound during SOVALDI + ribavirin treatment occurred in 2 subjects (0.9%) on antiretroviral therapy.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34069-5">
<div class="drugSubheadings">
<span id="SOVALDI_34069-5" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>16	HOW SUPPLIED/STORAGE AND HANDLING</div>
<div id="SOVALDI_previewText_34069-5" class="previewText">
                  SOVALDI tablets are yellow, capsule-shaped, film-coated table<span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34069-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p>SOVALDI tablets are yellow, capsule-shaped, film-coated tablets containing 400 mg sofosbuvir debossed with "GSI" on one side and "7977" on the other side.  Each bottle contains 28 tablets (NDC 61958-1501-1), a silica gel desiccant and polyester coil with a child-resistant closure.</p>
               </text></div>
<span id="SOVALDI_collapsableElement_" class="safetySubheading"></span><div id="44425-7" class="safetySubdescription"><text>
                        <p>Store at room temperature below 30 °C (86 °F).</p>
                        <ul ultype="unordered">
                           <li>Dispense only in original container</li>
                           <li>Do not use if seal over bottle opening is broken or missing</li>
                        </ul>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34076-0">
<div class="drugSubheadings">
<span id="SOVALDI_34076-0" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>17	PATIENT COUNSELING INFORMATION</div>
<div id="SOVALDI_previewText_34076-0" class="previewText">
                  Advise the patient to read the FDA-approved patient labeling <span>...</span>
</div>
</div>
<div id="SOVALDI_collapsableElement_34076-0" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p>Advise the patient to read the FDA-approved patient labeling (Patient Information).</p>
               </text></div>
<span id="SOVALDI_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Serious Symptomatic Bradycardia When Coadministered with Amiodarone and Another HCV Direct Acting Antiviral</content>
                        </p>
                        <p>Advise patients to seek medical evaluation immediately for symptoms of bradycardia such as near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion or memory problems <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S6.2">Adverse Reactions (6.2)</a>, and <a href="#S7.1">Drug Interactions (7.1)</a>]</content>.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Pregnancy</content>
                        </p>
                        <p>Advise patients to avoid pregnancy during combination treatment with SOVALDI and ribavirin or SOVALDI and peginterferon and ribavirin. Inform patients to notify their health care provider immediately in the event of a pregnancy <content stylecode="italics"> [see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</content>.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Drug Interactions</content>
                        </p>
                        <p>Advise patients that SOVALDI may interact with some drugs; therefore, patients should be advised to report the use of any prescription, non-prescription medication or herbal products to their healthcare provider <content stylecode="italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a> and <a href="#S7.1">Drug Interactions (7.1)</a>]</content>.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Hepatitis C Virus Transmission</content>
                        </p>
                        <p>Inform patients that the effect of treatment of hepatitis C infection on transmission is not known, and that appropriate precautions to prevent transmission of the hepatitis C virus during treatment or in the event of treatment failure should be taken.</p>
                     </text></div>
<span id="SOVALDI_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Important Information on Co-Administration with Ribavirin or Peginterferon and Ribavirin</content>
                        </p>
                        <p>Advise patients that the recommended regimen for patients with genotype 1 or 4 HCV infection is SOVALDI administered in combination with peginterferon alfa and ribavirin and the recommended regimen for patients with genotype 2 or 3 HCV infection is SOVALDI administered in combination with ribavirin. If peginterferon and/or ribavirin are permanently discontinued, SOVALDI should also be discontinued.</p>
                     </text></div>
</div>
</div>
<div class="section"><div id="SOVALDI_collapsableElement_42229-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>Manufactured and distributed by:<br>Gilead Sciences, Inc.<br>Foster City, CA 94404</p>
                  <p>SOVALDI is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.</p>
                  <p>©2015 Gilead Sciences, Inc. All rights reserved.</p>
                  <p>204671-GS-003</p>
               </text></div></div></div>
<div class="section"></div>
<div class="section"><div id="SOVALDI_collapsableElement_42229-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>Manufactured and distributed by:<br>Gilead Sciences, Inc.<br>Foster City, CA 94404</p>
                  <p>Issued:   August 2015</p>
                  <p>SOVALDI and HARVONI are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.</p>
                  <p>©2015 Gilead Sciences, Inc. All rights reserved.</p>
                  <p>204671-GS-003</p>
               </text></div></div></div>
<div class="section"></div>
</div>